Heron Therapeutics (HRTX)
(Delayed Data from NSDQ)
$2.45 USD
-0.10 (-3.92%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.45 0.00 (0.00%) 7:16 PM ET
2-Buy of 5 2
D Value A Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
HRTX 2.45 -0.10(-3.92%)
Will HRTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for HRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HRTX
Compared to Estimates, Heron Therapeutics (HRTX) Q4 Earnings: A Look at Key Metrics
Oncternal Therapeutics (ONCT) Reports Q4 Loss, Tops Revenue Estimates
HRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Curious about Heron Therapeutics (HRTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates
Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics
Other News for HRTX
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday